Amphastar Pharmaceuticals (NASDAQ:AMPH) Downgraded by StockNews.com

StockNews.com cut shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a buy rating to a hold rating in a report issued on Sunday morning.

A number of other research firms have also weighed in on AMPH. Needham & Company LLC reaffirmed a hold rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Piper Sandler reduced their price objective on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an overweight rating on the stock in a research report on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Hold and an average price target of $63.00.

Amphastar Pharmaceuticals Trading Up 0.2 %

NASDAQ AMPH opened at $48.56 on Friday. The company has a debt-to-equity ratio of 0.88, a current ratio of 2.18 and a quick ratio of 1.72. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of 16.80, a PEG ratio of 0.75 and a beta of 0.79. The business’s fifty day moving average is $41.70 and its 200-day moving average is $43.23. Amphastar Pharmaceuticals has a one year low of $36.56 and a one year high of $65.92.

Insider Activity

In related news, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the completion of the transaction, the director now owns 78,409 shares of the company’s stock, valued at approximately $3,246,132.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CFO William J. Peters sold 10,282 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $44.23, for a total value of $454,772.86. Following the completion of the transaction, the chief financial officer now owns 94,103 shares in the company, valued at $4,162,175.69. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the transaction, the director now directly owns 78,409 shares in the company, valued at approximately $3,246,132.60. The disclosure for this sale can be found here. Insiders sold a total of 38,479 shares of company stock valued at $1,677,422 in the last 90 days. Company insiders own 27.10% of the company’s stock.

Institutional Trading of Amphastar Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quadrant Capital Group LLC raised its position in shares of Amphastar Pharmaceuticals by 27.8% in the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock valued at $63,000 after purchasing an additional 223 shares during the last quarter. Bridge City Capital LLC lifted its position in Amphastar Pharmaceuticals by 0.8% during the first quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock worth $1,527,000 after buying an additional 275 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in Amphastar Pharmaceuticals by 2.5% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 11,300 shares of the company’s stock valued at $452,000 after purchasing an additional 275 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 23.9% during the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after purchasing an additional 309 shares during the period. Finally, Nations Financial Group Inc. IA ADV boosted its position in shares of Amphastar Pharmaceuticals by 2.7% during the 1st quarter. Nations Financial Group Inc. IA ADV now owns 14,923 shares of the company’s stock worth $655,000 after purchasing an additional 399 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.